索拉非尼维持治疗用于FLT3内部串联重复突变急性髓系白血病异基因造血干细胞移植后(SORMAIN)
SORMAIN随机双盲安慰剂对照II期试验纳入83例FLT3-ITD阳性AML异基因HCT后完全血液学缓解成人患者,索拉非尼组43例、安慰剂组40例,治疗24个月。中位随访41.8个月,索拉非尼组复发或死亡HR 0.39(95%CI 0.18-0.85;P=.013),24个月RFS概率索拉非尼组85.0% vs 安慰剂组53.3%。结论:索拉非尼维持治疗降低HCT后复发和死亡风险。
要点
- 索拉非尼组复发或死亡风险低于安慰剂组,HR 0.39(95%CI 0.18-0.85;P=.013)。
- 24个月无复发生存概率索拉非尼组85.0% vs 安慰剂组53.3%(HR 0.256;95%CI 0.10-0.65;P=.002)。
- 探索性数据显示HCT前MRD不可测及HCT后MRD可测者从索拉非尼获益最强。
核心结论
- 索拉非尼维持治疗降低FLT3-ITD阳性AML异基因HCT后复发和死亡风险。
研究设计与样本
- 随机、安慰剂对照、双盲II期试验(SORMAIN;德国临床试验注册号DRKS00000591)。
- 83例FLT3-ITD阳性AML成人患者,异基因HCT后完全血液学缓解,随机接受索拉非尼43例或安慰剂40例,疗程24个月。
- 主要终点为无复发生存(RFS),复发定义为复发或死亡,以先发生者为准。
主要发现
- 中位随访41.8个月,索拉非尼组 vs 安慰剂组复发或死亡HR 0.39(95%CI 0.18-0.85;log-rank P=.013)。
- 24个月RFS概率安慰剂组53.3%(95%CI 0.36-0.68) vs 索拉非尼组85.0%(95%CI 0.70-0.93)(HR 0.256;95%CI 0.10-0.65;log-rank P=.002)。
- 探索性数据显示HCT前MRD不可测的患者及HCT后MRD可测的患者从索拉非尼获益最强。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Despite undergoing allogeneic hematopoietic stem cell transplantation (HCT), patients with acute myeloid leukemia (AML) with internal tandem duplication mutation in the FMS-like tyrosine kinase 3 gene (FLT3-ITD) have a poor prognosis, frequently relapse, and die as a result of AML. It is currently unknown whether a maintenance therapy using FLT3 inhibitors, such as the multitargeted tyrosine kinase inhibitor sorafenib, improves outcome after HCT. PATIENTS AND METHODS: In a randomized, placebo-controlled, double-blind phase II trial (SORMAIN; German Clinical Trials Register: DRKS00000591), 83 adult patients with FLT3-ITD-positive AML in complete hematologic remission after HCT were randomly assigned to receive for 24 months either the multitargeted and FLT3-kinase inhibitor sorafenib (n = 43) or placebo (n = 40 placebo). Relapse-free survival (RFS) was the primary endpoint of this trial. Relapse was defined as relapse or death, whatever occurred first. RESULTS: With a median follow-up of 41.8 months, the hazard ratio (HR) for relapse or death in the sorafenib group versus placebo group was 0.39 (95% CI, 0.18 to 0.85; log-rank P = .013). The 24-month RFS probability was 53.3% (95% CI, 0.36 to 0.68) with placebo versus 85.0% (95% CI, 0.70 to 0.93) with sorafenib (HR, 0.256; 95% CI, 0.10 to 0.65; log-rank P = .002). Exploratory data show that patients with undetectable minimal residual disease (MRD) before HCT and those with detectable MRD after HCT derive the strongest benefit from sorafenib. CONCLUSION: Sorafenib maintenance therapy reduces the risk of relapse and death after HCT for FLT3-ITD-positive AML.
引用
- Burchert A, Bug G, Fritz LV, et al. Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN). J Clin Oncol. 2020. PMID: 32673171. doi:10.1200/JCO.19.03345
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。